| P50 | author | Ian D Maidment | Q56332638 |
| | Jon Wilson | Q84878580 |
| | Asta R Prajapati | Q87030605 |
| P2093 | author name string | Fujian Song | |
| P2860 | cites work | Efficacy and safety of second-generation antipsychotic long-acting injections (SGA LAIs) in maintenance treatment of bipolar disorder: protocol for a systematic review and meta-analysis | Q28078078 |
| | Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis | Q28266069 |
| | Systematic review of patient and nurse attitudes to depot antipsychotic medication. | Q31013400 |
| | Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials | Q34160338 |
| | Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder | Q34267385 |
| | Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology | Q34676317 |
| | A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder | Q35965634 |
| | Depot antipsychotic medications in bipolar disorder: a review of the literature | Q36905876 |
| | A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder | Q37632466 |
| | What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder? | Q38116564 |
| | Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study | Q38381456 |
| | Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials. | Q38840490 |
| | Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization | Q40623890 |
| | Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder | Q43130555 |
| | A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently | Q43239518 |
| | Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. | Q46903473 |
| | A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder | Q48697520 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. | Q52656684 |
| | A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. | Q55054009 |
| | A Pilot, 15-month, randomised effectiveness trial of Risperidone long-acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder | Q60460522 |
| | Depot antipsychotics in the prophylaxis of bipolar affective disorder | Q72609469 |
| | A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder | Q80771740 |
| P433 | issue | 8 | |
| P921 | main subject | bipolar disorder | Q131755 |
| | systematic review | Q1504425 |
| P304 | page(s) | 687-696 | |
| P577 | publication date | 2018-11-11 | |
| P1433 | published in | Bipolar Disorders | Q15716681 |
| P1476 | title | Second-generation antipsychotic long-acting injections in bipolar disorder: Systematic review and meta-analysis | |
| P478 | volume | 20 | |